Achmea Investment Management B.V. bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 426,615 shares of the company’s stock, valued at approximately $53,134,000. Johnson & Johnson makes up 2.5% of Achmea Investment Management B.V.’s investment portfolio, making the stock its 3rd largest position.

Several other hedge funds have also modified their holdings of the stock. State Street Corp increased its position in shares of Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $3,220,322,000. Schwab Charles Investment Management Inc. increased its position in shares of Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock valued at $1,388,775,000 after buying an additional 201,703 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock valued at $1,381,745,000 after buying an additional 136,764 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock valued at $990,041,000 after buying an additional 42,144 shares in the last quarter. Institutional investors and hedge funds own 66.10% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded up 0.79% on Wednesday, reaching $134.44. 1,475,386 shares of the company were exchanged. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company’s 50-day moving average price is $132.93 and its 200 day moving average price is $126.81. The company has a market cap of $360.84 billion, a price-to-earnings ratio of 22.75 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter last year, the business earned $1.74 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s payout ratio is 56.76%.

ILLEGAL ACTIVITY WARNING: “Achmea Investment Management B.V. Takes Position in Johnson & Johnson (JNJ)” was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/achmea-investment-management-b-v-takes-position-in-johnson-johnson-jnj/1495675.html.

Several equities analysts recently issued reports on the stock. BTIG Research downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target for the company. in a report on Friday, July 21st. Atlantic Securities downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Finally, Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a report on Thursday, July 20th. They set an “outperform” rating and a $148.00 price target for the company. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $134.12.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.